Abstract
In a double-blind study on healthy subjects who underwent three 3-week periods of treatment with metoprolol (M) + sulfinpyrazone (S), M + placebo, and S + placebo, pharmacokinetics and plasma levels of M were not affected by concurrent administration of S. Analysis of variance change-over demonstrated a significant difference between treatments only for serum uric acid levels. Analysis of post-treatment and baseline data within each treatment showed: decreased platelet count by M, lowered serum 6-keto PGF1α by all three treatments, decreased serum TXB2 generation and arachidonic acid-induced platelet aggregation by S + M. No negative interaction between S + M was found.
Original language | English |
---|---|
Pages (from-to) | 65-74 |
Number of pages | 10 |
Journal | Thrombosis Research |
Volume | 34 |
Issue number | 1 |
DOIs | |
Publication status | Published - Apr 1 1984 |
Keywords
- Metoprolol
- platelet function
- sulfinpyrazone
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Hematology